CSIMarket Company Name, Ticker, Competitors, else..
 
Artelo Biosciences Inc   (NASDAQ: ARTL)
Other Ticker:  
 
 
Price: $1.3300 $-0.05 -3.623%
Day's High: $1.3982 Week Perf: 12.69 %
Day's Low: $ 1.30 30 Day Perf: 15.36 %
Volume (M): 35 52 Wk High: $ 1.75
Volume (M$): $ 47 52 Wk Avg: $1.29
Open: $1.40 52 Wk Low: $0.91



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 3
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Artelo Biosciences Inc
Artelo Biosciences Inc is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics targeting the endocannabinoid system for the treatment of various diseases and conditions. The company focuses on developing drugs that modulate the endocannabinoid system to address pain, inflammation, and cancer-related symptoms. Artelo's pipeline includes candidates for cancer-related anorexia and weight loss, opioid reduction in cancer patients, and arthritis. They aim to provide safe and effective treatment options to improve the lives of patients suffering from these conditions.


   Company Address: 505 Lomas Santa Fe Solana Beach 92075 CA
   Company Phone Number: 925-7049   Stock Exchange / Ticker: NASDAQ ARTL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN        2.39% 
ITCI   -0.14%    
JAZZ   -1.38%    
PFE   -0.77%    
SRPT   -1.75%    
VRTX   -3%    
• View Complete Report
   



Product Service News

Promising Phase 1 Data from CAReS Trial Demonstrates Safety and Efficacy of ART27.13 in Cancer-Related Anorexia

Published Mon, Dec 30 2024 7:37 PM UTC

Abstract: Artelo Biosciences has announced significant findings from its Phase 1 clinical trial (CAReS) evaluating ART27.13, an investigational treatment for cancer-related anorexia. The results indicate a favorable safety profile and highlight the potential therapeutic benefits of this agent, with a notable proportion of participants achieving stabilization or reversal of w...
Product Service News

Artelo Biosciences, a trailblazer in the biopharmaceutical industry, continues to make significant strides ...

Published Wed, Nov 13 2024 1:30 PM UTC

Cutting-Edge Advances in Pain and Anxiety Management: Artelo Biosciences Groundbreaking Discoveries in Non-Opioid Treatments Artelo Biosciences, a trailblazer in the biopharmaceutical industry, continues to make significant strides in the development of novel non-opioid treatment options, showcasing their unwavering commitment to addressing some of the most prevalent challe...
Product Service News

ART26.12 Pioneering a Paradigm Shift in Painful Neuropathies Treatment, with a Focus on Chemotherapy-induced Peripher...

Published Mon, Jul 15 2024 12:30 PM UTC

Artelo Biosciences Receives FDA Clearance for ART26.12: A Promising Breakthrough in Painful Neuropathies Treatment Addressing the Unmet Need in Painful NeuropathiesPainful neuropathies, such as chemotherapy-induced peripheral neuropathy (CIPN), pose significant challenges to patients and healthcare providers alike. These conditions, characterized by intense pain, numbness, a...
Product Service News

Preclinical Studies Highlight ART12.11?s Potential in Treating Anxiety-Related Disorders An Examination ...

Published Wed, Jul 3 2024 1:00 PM UTC

Artelo Biosciences recently presented a series of compelling preclinical studies on their investigational therapy, ART12.11, at the 34th Annual International Cannabinoid Research Society Symposium. The findings indicate that ART12.11 could be a superior product candidate for the treatment of anxiety-related disorders. Study Details The comprehensive preclinical research eval...
Clinical Study

Artelo Biosciences Breakthrough: ART12.11 Shows Comparable Pharmacokinetics to Epidiole...

Published Wed, May 29 2024 12:30 PM UTC

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 Artelo Biosciences Inc., a leading biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics, has recently showcased highly promising data for their novel investigational therapy, ART12.11, at the CT-CANN24 confere...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com